ES2185630T3 - Nuevos polipeptidos y peptidos, acidos nucleicos que los codifican, y su utilizacion en el campo de la terapia de tumores, inflamacion o inmunologia. - Google Patents
Nuevos polipeptidos y peptidos, acidos nucleicos que los codifican, y su utilizacion en el campo de la terapia de tumores, inflamacion o inmunologia.Info
- Publication number
- ES2185630T3 ES2185630T3 ES93909852T ES93909852T ES2185630T3 ES 2185630 T3 ES2185630 T3 ES 2185630T3 ES 93909852 T ES93909852 T ES 93909852T ES 93909852 T ES93909852 T ES 93909852T ES 2185630 T3 ES2185630 T3 ES 2185630T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- acid sequence
- polypeptides
- polipeptides
- codify
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 206010061218 Inflammation Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LA INVENCION SE REFIERE: A UN POLIPEPTIDO QUE CONTIENE EN SU CADENA PEPTIDICA LA SECUENCIA DE AMINOACIDO DE 311 AMINOACIDOS DE LA FIG. 3, O UN FRAGMENTO DE ESTA SECUENCIA, SIENDO EL FRAGMENTO TAL QUE PUEDA PRODUCIR ANTICUERPOS CAPACES DE FORMAR UN COMPLEJO CON LA SECUENCIA DE AMINOACIDO DE LA FIG. 3, O UNA SECUENCIA DE AMINOACIDO QUE TENGA UN PORCENTAJE DE HOMOLOGIA DE AL MENOS UN 50%, PREFERIBLEMENTE UN 75%, Y MAS VENTAJOSAMENTE UN 90% CON LA SECUENCIA DE AMINOACIDO DE LA FIG. 3, Y A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN, COMO SUSTANCIA ACTIVA, AL MENOS UNO DE LOS POLIPEPTIDOS DE LA INVENCION O DE LOS ANTAGONISTAS DE LOS POLIPEPTIDOS DE LA INVENCION COMO COMPUESTOS ANTITUMORALES, O COMPUESTOS ANTIINFLAMATORIOS O COMO ACTIVADORES DEL CRECIMIENTO DE LAS CELULAS T Y LAS CELULAS B, COMO COMPUESTOS PARA LA REPARACION DEL HUESO COMO INDUCTORES DE LAS CELULAS INMUNOSUPRESORAS, COMO INHIBIDORES DEL FACTOR DEL ESTIMULACION ANTI-COLONIAS; O COMO AGENTES TRIPANOCIDAS; O PARTE DE LOS POLIPEPTIDOS DE LA INVENCION CAPACES DE UNIRSE AL RECEPTOR ANTES DEFINIDO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92401231 | 1992-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2185630T3 true ES2185630T3 (es) | 2003-05-01 |
Family
ID=8211656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES93909852T Expired - Lifetime ES2185630T3 (es) | 1992-04-30 | 1993-04-28 | Nuevos polipeptidos y peptidos, acidos nucleicos que los codifican, y su utilizacion en el campo de la terapia de tumores, inflamacion o inmunologia. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5981277A (es) |
| EP (1) | EP0639225B1 (es) |
| JP (1) | JPH07502171A (es) |
| AT (1) | ATE226250T1 (es) |
| DE (1) | DE69332406T2 (es) |
| DK (1) | DK0639225T3 (es) |
| ES (1) | ES2185630T3 (es) |
| PT (1) | PT639225E (es) |
| WO (1) | WO1993022437A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995023862A1 (en) * | 1994-03-04 | 1995-09-08 | Ludwig Institute For Cancer Research | Animals with targeted gene disruption |
| DE19846077C2 (de) * | 1998-10-06 | 2000-09-07 | Ulrich H Goeringer | Trypanosomen-bindende Nukleinsäuren, ihre Herstellung und Verwendung |
| EP1233779A2 (en) * | 1999-11-30 | 2002-08-28 | Innogenetics N.V. | New uses of suppressive macrophage activation factors |
| US7329725B1 (en) | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
| BRPI0509278A (pt) | 2004-03-30 | 2007-09-18 | Nsgene As | polipeptìdeo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira isolada, linhagem de célula empacotadora, dispositivo celular biocompatìvel implantável, composição farmacêutica, uso do polipeptìdeo, ou da seqüência de ácido nucléico isolada, ou do vetor de expressão, ou de uma composição de células hospedeiras, ou de um dispositivo celular biocompatìvel implantável ou de uma linhagem de célula empacotadora, método de tratamento de uma condição patológica em um indivìduo, métodos para prevenir a apoptose em uma célula neuronal de mamìfero, para realçar a sobrevivência de uma célula neuronal de mamìfero, para gerar um neurÈnio, para expandir uma composição de células de mamìfero, e para diferenciar uma composição de células de mamìfero, anticorpo, e, imunoconjugado |
| BRPI0618857B1 (pt) * | 2005-11-25 | 2022-07-19 | Zoetis Belgium S.A | Oligonucleotídeo de rna isolado, e método para regular negativamente células reguladoras cd4+ imunossupressoras |
| EP2195013B1 (en) * | 2008-07-24 | 2011-11-02 | NsGene A/S | Therapeutic use of a growth factor, metrnl |
| JP6149226B2 (ja) | 2010-10-01 | 2017-06-21 | ホーバ セラピューティクス アンパルトセルスカブ | アロディニア、痛覚過敏、自発痛及び幻肢痛の処置 |
| US9474786B2 (en) | 2011-09-05 | 2016-10-25 | Nsgene A/S | Treatment of allodynia |
| US10717992B2 (en) * | 2013-01-25 | 2020-07-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn |
| WO2015062167A1 (zh) * | 2013-10-29 | 2015-05-07 | 中国人民解放军第二军医大学 | Metrnl蛋白在制备降血脂降血糖药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6490199A (en) * | 1987-09-30 | 1989-04-06 | Hiromi Fujiwara | T cell growth factor derived from thymic interstitial cell and production thereof |
| US5049659A (en) * | 1988-02-09 | 1991-09-17 | Dana Farber Cancer Institute | Proteins which induce immunological effector cell activation and chemattraction |
-
1993
- 1993-04-28 JP JP5518910A patent/JPH07502171A/ja active Pending
- 1993-04-28 EP EP93909852A patent/EP0639225B1/en not_active Revoked
- 1993-04-28 ES ES93909852T patent/ES2185630T3/es not_active Expired - Lifetime
- 1993-04-28 US US08/318,837 patent/US5981277A/en not_active Expired - Fee Related
- 1993-04-28 DE DE69332406T patent/DE69332406T2/de not_active Revoked
- 1993-04-28 DK DK93909852T patent/DK0639225T3/da active
- 1993-04-28 PT PT93909852T patent/PT639225E/pt unknown
- 1993-04-28 WO PCT/EP1993/001022 patent/WO1993022437A1/en not_active Application Discontinuation
- 1993-04-28 AT AT93909852T patent/ATE226250T1/de not_active IP Right Cessation
-
1999
- 1999-04-19 US US09/294,121 patent/US20020069422A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US5981277A (en) | 1999-11-09 |
| EP0639225A1 (en) | 1995-02-22 |
| US20020069422A1 (en) | 2002-06-06 |
| EP0639225B1 (en) | 2002-10-16 |
| DK0639225T3 (da) | 2003-02-17 |
| PT639225E (pt) | 2003-03-31 |
| JPH07502171A (ja) | 1995-03-09 |
| DE69332406T2 (de) | 2003-06-26 |
| DE69332406D1 (de) | 2002-11-21 |
| ATE226250T1 (de) | 2002-11-15 |
| WO1993022437A1 (en) | 1993-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105616T1 (el) | ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1 | |
| ES2185630T3 (es) | Nuevos polipeptidos y peptidos, acidos nucleicos que los codifican, y su utilizacion en el campo de la terapia de tumores, inflamacion o inmunologia. | |
| CO4890856A1 (es) | CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP | |
| PT73161A (fr) | Procede pour la preparation de derives de n-(vynblastinoyl-23) aux amino-acids et peptides et son application terapeutique | |
| ES2139012T3 (es) | Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana. | |
| AR012540A1 (es) | COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN | |
| UY23561A1 (es) | Procedimiento para la preparacion de tnf-muteinas | |
| FI951987A (fi) | Verisuoniin liittyvien endoteliaaliseen solukasvutekijän antagonistit | |
| ATE298561T1 (de) | Orale dareichungsform | |
| NO960630D0 (no) | Heterocykler anvendelige som neurokinin antagonister | |
| AR247590A1 (es) | Una secuencia de adn que codifica derivados de factor viii humano recombinante y un procedimiento para su obtencion | |
| BR9811094A (pt) | Agente terapêutico para tumores linfáticos | |
| ES2144394T3 (es) | Polipeptidos y peptidos recombinantes, acidos nucleicos que los codifican y utilizacion de dichos polipeptidos y peptidos para el diagnostico de la tuberculosis. | |
| ES2053454T3 (es) | Composiciones farmaceuticas que contienen peptidos del grupo de la colecistoquinina-ceruleina para la terapia de estados de shock y de insuficiencias respiratorias y cardiocirculatorias. | |
| ES2144418T3 (es) | Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario. | |
| ES8606411A1 (es) | Procedimiento para la determinacion de fibrina | |
| DE60331574D1 (de) | Verfahren zur behandlung von erkrankungen mit mangel an thiolhaltiger verbindung | |
| DE69528531D1 (de) | D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet | |
| AR020101A1 (es) | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. | |
| ATE359296T1 (de) | Pharmazeutische peptide formulierungen zur behandlung von staubmilben allergie | |
| TR199902866T2 (xx) | Organo- koruyucu aktiviteye sahip yeni BPC peptid tuzlar�, haz�rlanmalar� ve terapide kullan�lmalar� i�in prosesler. | |
| AR245958A1 (es) | Procedimiento para la preparacion de polipeptidos de interleucina-1alfa | |
| ES2162068T3 (es) | Peptidos que ligan el factor ix, derivados del factor viii y su utilizacion como inhibidores de la coagulacion de la sangre. | |
| SE8402199D0 (sv) | Pharmazeutisches preparat enthaltend co-dergocrine und einen calcium-antagonisten | |
| ATE283279T1 (de) | Therapeutische inhaltsstoffe |